ESMO24

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

ESMO24
Jan 8, 2025, 15:34 | Insight
Sophia Wong: Full proofs of our review on solid tumour cellular therapy toxicity management
Sophia Wong, Assistant Professor, and Medical Oncologist at the National Cancer Centre Singapore, shared a…
Nov 27, 2024, 15:56 | Blog
Vivek Subbiah: ESMO24 and an AACR debate is at Healthcare Unfiltered podcast
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a…
Nov 9, 2024, 20:08 | Blog
Dr. Sara Tolaney Discusses ESMO24 Insights on TroFuse-010 Trial in Advanced Breast Cancer
Dana-Farber’s Breast Oncology Center shared the following on X: “Dr. Sara Tolaney discussed ESMO24 Insights…
Nov 6, 2024, 12:41 | Blog
Jon Lim: Final call for our "Manchester post-ESMO24 Highlights Event"
Jon Lim, Medical Oncologist and Postdoctoral Clinical Fellow at The Francis Crick Institute, posted on…
Nov 1, 2024, 06:05 | Blog
Pawel Sobczuk about pharmaceutical wastage in the US on "One Health" column by ESMO
ESMO - European Society for Medical Oncology shared a post on LinkedIn: " The United States waste…
Oct 29, 2024, 17:33 | Blog
Practice-changing ESMO24 genitourinary trials with Anthony Joshua - Oncology for the Inquisitive Mind
Oncology for the Inquisitive Mind shared a post on X: "Professor Anthony Joshua returns for…
Oct 29, 2024, 10:29 | Blog
Guru Sonpavde: Pleased to discuss bladder cancer highlights at ESMO East conference
Guru Sonpavde posted on LinkedIn: "ESMO24 bladder cancer highlights: Pleased to discuss from AdventHealth Central…
Oct 23, 2024, 10:40 | Insight
Paolo Tarantino: Final iDFS results from NATALEE published in Annals of Oncology
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared…
Oct 22, 2024, 16:29 | Blog
Matthias Guckenberger: Honored to represent ESTRO at international meetings
Matthias Guckenberger, Radiation Oncologist at University Hospital Zurich, posted the following on LinkedIn: “Exciting weeks have…
Oct 21, 2024, 19:19 | Blog
Guru Sonpavde: Potentially practice-changing highlights from 2 key Phase III clinical trials
Guru Sonpavde shared a post on LinkedIn: ''ESMO24 bladder cancer potentially practice-changing highlights from 2…
Oct 21, 2024, 12:48 | Insight
An expert's take on colorectal cancer highlights
Oncology for the Inquisitive Mind shared a post on X: “With ESMO24 done, Michael and…
Oct 18, 2024, 16:52 | Blog
Oncology Brothers: Lung Cancer Highlights from ESMO24 with Stephen V Liu
Oncology Brothers posted on X: "Lung Cancer Highlights ESMO24 with Stephen V Liu Updates on:…
Oct 14, 2024, 12:36 | Insight
Updated data of KEYNOTE-716 and CheckMate 76K studies at ESMO24
The European Society for Medical Oncology (ESMO) shared a post on X: "At ESMO24, updated…
Oct 12, 2024, 11:52 | Blog
Oncology Brothers: GI Malignancy Highlights from ESMO24 with Kristen Ciombor
Oncology Brothers posted on X: "GI Malignancy Highlights from ESMO24 with Kristen Ciombor LEAP012 KN811…
Oct 11, 2024, 19:53 | Blog
Rahul Gosain: GI Malignancy Highlights from ESMO24
Rahul Gosain shared a post about GI Malignancy Highlights. Read his post on LinkedIn below:…
Oct 11, 2024, 17:45 | Blog
Andrea Apolo about the latest trials and practice changes in bladder cancer
Bogdana Schmidt, Urologic Oncologist at Huntsman Cancer Institute, shared a post about a conversation with…
Oct 8, 2024, 13:37 | Blog
Tanja Spanic: What an incredible September it has been
Tanja Spanic shared a post on LinkedIn: ''What an incredible September it has been! This…
Oct 8, 2024, 13:11 | Blog
Elisa Agostinetto: The practice-changing results of the HypoG-01 UNICANCER trial at ESMO24
Elisa Agostinetto shared a post by MediMix, on X, adding: ''At ESMO24 the practice-changing results…
Oct 6, 2024, 12:55 | Blog
Rahul Gosain: GU Malignancy Highlights from ESMO24 with Petros Grivas
Rahul Gosain shared on LinkedIn: "GU Malignancy Highlights from ESMO24 with Petros Grivas: - NIAGARA…
Oct 5, 2024, 09:09 | Insight
Sunil Verma: AstraZeneca’s vision to redefine cancer care
Sunil Verma shared on LinkedIn: “ I had the pleasure of sitting down with Hannah…
Oct 4, 2024, 17:19 | Blog
Bishal Gyawali: Our CSO Symposium in Vall d’Hebron Hospital
Bishal Gyawali shared a post on X: "I had the pleasure of speaking with Oncoinfo during…
Oct 4, 2024, 15:15 | Blog
Paolo Tarantino: An interesting biomarker study of DB04. Two notable findings at ESMO24
Paolo Tarantino shared a post on X: "Among the many great ESMO24 posters there was…
Oct 1, 2024, 14:00 | Blog
Amil Družić: European School of Oncology to support young oncology professionals in the early stages of their careers
Amil Družić shared a post on Linkedin: ''European School of Oncology has been instrumental in…
Oct 1, 2024, 09:29 | Blog
Paolo Tarantino's ESMO24 top 5 breast cancer presentations and takeaway messages
Paolo Tarantino shared a post by Sameh Abdelmalak, Director, Oncology, Educational Partnerships at VuMedi, on X, adding:…
Sep 30, 2024, 16:12 | Blog
Triparna Sen: Honored to participate in the Lung Cancer America patient advocacy workshop
Triparna Sen, Associate Professor, Icahn School of Medicine at Mount Sinai, shared a post on X:…
Sep 29, 2024, 14:41 | Blog
Increasing the knowledge of pharmacologic interventions targeting cancer and treatment-related symptoms at ESMO24
ESMO posted on LinkedIn: "Well-designed multicenter randomised clinical trials are paramount to collect evidence and…
Sep 27, 2024, 15:09 | Blog
Oncogene-addicted NSCLC highlights from WCLC24 and ESMO24 - Lung Connect
Herbert Loong shared a post by LUNG CONNECT on LinkedIn, adding: "Thanks LUNG CONNECT for providing me w/…
Sep 27, 2024, 14:59 | Blog
Sébastien Couraud: Alexis Cortot about air pollutants interactions with lung cancers molecular alerations
Jill Feldman shared a post by Sébastien Couraud, Professor of Pulmonology, Université Lyon, on X, adding:…
Sep 26, 2024, 17:57 | Insight
Results from the ABIGAIL study presented at ESMO24
ESMO - European Society for Medical Oncology shared a post on LinkedIn: "At ESMO24 results…
Sep 26, 2024, 14:22 | Blog
Luis Castelo-Branco: Belzutifan vs everolimus for advanced kidney cancer
Luis Castelo-Branco shared a post on X: ''Belzutifan vs everolimus for advanced kidney cancer: NO…
Sep 25, 2024, 15:17 | Blog
Bishal Gyawali: My talk at the Common Sense Oncology symposium during ESMO24 is now available
Bishal Gyawali shared on X: "Recording from my talk at the Common Sense Oncology symposium…
Sep 25, 2024, 15:10 | Blog
Giannis Mountzios: Still confused after info/data overload from WCLC24 and ESMO24?
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General Hospital,…
Sep 24, 2024, 22:58 | Blog
Isabelle Schmitt-Opitz: Session on 'Promises and Pitfalls in Earlier Stage NSCLC' at ESMO24
Isabelle Schmitt-Opitz shared a post on LinkedIn: ''It was a pleasure to chair this highly…
Sep 24, 2024, 17:11 | Blog
Guru Sonpavde: ESMO24 bladder cancer highlight HRQoL outcomes from CheckMate 901 trial
Guru Sonpavde shared a post on LinkedIn: "ESMO24 bladder cancer highlight: Health-related quality of life (HRQoL)…
Sep 24, 2024, 13:31 | Blog
Sabine D. Brookman-May: MA supports EFS as a surrogate for OS in Muscle invasive bladder cancer after neoadjuvant treatment
Sabine D. Brookman-May shared a post on X: ''This MA supports Event-free survival as a…
Sep 24, 2024, 11:40 | Blog
Neil D. Gross: Neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma
Neil D. Gross, The Director of Clinical Research in the Department of Head and Neck…
Sep 24, 2024, 05:30 | Insight
Ana I. Velázquez Mañana: Best Poster in Urothelial Cancers at ESMO24 by Amanda Nizam
Ana I. Velázquez Mañana shared a post on X: "Congratulations Amanda Nizam, mentor Vadim Koshkin…
Sep 23, 2024, 23:54 | Blog
Sylwia Biszczuk: Reflecting on the ESMO annual congress
Sylwia Biszczuk, Medical Network and Operations Manager at Further Group, posted on LinkedIn: "As we are…
Sep 23, 2024, 20:18 | Blog
Antonio Passaro: Honored to have presented the SOHO-02 clinical trial
Antonio Passaro shared a post on LinkedIn: "I am truly honored to have presented the…
Sep 23, 2024, 15:50 | Insight
Guru Sonpavde: ESMO24 bladder cancer practice-changing highlight
Guru Sonpavde, Genitourinary Oncology and Phase I Clinical Trials Director of Chair of Bladder Cancer…
Sep 23, 2024, 13:52 | Blog
Wungki Park: Polar Maintenance: Promising Outcomes in BRCA HRD Cohorts with Pembro + Olaparib
Wungki Park, Gastrointestinal Oncologist at the Memorial Sloan Kettering Cancer Center, shared on X: ''POLAR…
Sep 23, 2024, 00:12 | Insight
Elisa Agostinetto: FDA has approved adjuvant ribociclib based on the results of the NATALEE trial presented at ESMO24
Elisa Agostinetto shared a post by MediMix on LinkedIn, adding: “FDA has just approved adjuvant…
Sep 22, 2024, 16:32 | Blog
Davide Smussi: Thrilled to have participated in my first ESMO Congress
Davide Smussi, Resident in Medical Oncology - ASST Spedali Civili di Brescia, shared a post…
Sep 22, 2024, 15:58 | Blog
Omnia Korani: Thrilled to announce that my research poster has been presented at ESMO 2024
Omnia Korani, Assistant Lecturer at the National Cancer Institute, shared a post on LinkedIn: "Exciting…
Sep 22, 2024, 12:38 | Blog
Amol Akhade: Cabozantinib plus Atezolizumab vs second-line NHT in prostate cancer
Amol Akhade shared a post on LinkedIn: ''Cabozantinib plus Atezolizumab versus second-line Non-hormonal Therapy (NHT)…
Sep 22, 2024, 05:15 | Blog
Evandro de Azambuja: ESMO24 broke all records
Evandro de Azambuja shared a post on LinkedIn: "ESMO24 broke all records... and now a family…
Sep 21, 2024, 15:21 | Insight
Ulrike Harjes: Promising response rates with Nivolumab in TNBC patients
Ulrike Harjes, Senior Editor at Nature Medicine, posted the following on X: “Out now in Nature…
Sep 21, 2024, 14:21 | Blog
Elizabeth McKenna: Two Cancer Discovery papers that were published simultaneously with ESMO24
Elizabeth McKenna shared a post on LinkedIn, about recent papers published in AACR Journals: ''I'm…
Sep 21, 2024, 14:06 | Blog
Edgardo S. Santos: PCR after neoadjuvant is still not enough for cure
Edgardo S. Santos, Vice President of Florida Society of Clinical Oncology and Medical Director of…
Sep 21, 2024, 14:04 | Blog
Enrique Grande: Another practice changing trial in the back
Enrique Grande shared a post on X: ''NIAGARA is the first randomized trial to demonstrate…
Sep 21, 2024, 13:42 | Blog
Ishwaria Subbiah: The question to kickoff the ESMO Resilience Task Force Special Forum
Ishwaria Subbiah shared a post on X: '''What can we do to help individuals, systems,…
Sep 21, 2024, 13:13 | Blog
Florian Lordick: Niche2 data presented by Myriam Chalabi
Florian Lordick, Professor of Medicine at University of Leipzig and Director of the Comprehensive Cancer…
Sep 21, 2024, 13:10 | Blog
Daniel Sumarriva: Amy Abernethy on AI in Oncology at ESMO24
Daniel Sumarriva, Senior Director of Molecular Science Liaisons at Caris Life Sciences, shared a post…
Sep 21, 2024, 13:04 | Blog
Guru Sonpavde: Adjuvant pembrolizumab improved outcomes in MIBC
Guru Sonpavde, Genitourinary Oncology and Phase I Clinical Trials Director of Chair of Bladder Cancer…
Sep 21, 2024, 13:02 | Blog
Final OS data from the phase III CONTACT-02 trial at ESMO24
ESMO (European Society for Medical Oncology) shared a post on LinkedIn: ''Final OS data from…
Sep 21, 2024, 10:25 | Blog
Chris Cronin: First session of my ESMO24 is gonna be hard to top
Chris Cronin, Specialist Registar Medical Oncology, Beaumont Hospital Dublin, shared a post on X: "First…
Sep 21, 2024, 10:15 | Blog
Cristiane D Bergerot: Deb Maskens' dedication to advocating for patients with kidney cancer
Cristiane D Bergerot shared a post on X: "Always a pleasure to meet with Deb Maskens.…
Sep 21, 2024, 08:28 | Blog
Julie Hallet: Cabozantinib vs placebo for NETs
Julie Hallet, Associate Scientist at Sunnybrook Health Sciences Centre and Assistant Professor of General Surgery…
Sep 20, 2024, 23:18 | Blog
Yüksel Ürun: Key goals post ESMO24
Yüksel Ürun shared a post on LinkedIn: "Key goals post ESMO24 1.Integrate findings into practice…
Sep 20, 2024, 23:08 | Blog
Simrun Kaur-Rathore: I represented Technology In Cancer Research and Treatment at ESMO24
Simrun Kaur-Rathore, Associate Managing Editor on Technology In Cancer Research and Treatment, posted on LinkedIn:…
Sep 20, 2024, 18:09 | Blog
Marco Donia: Melanoma at ESMO24
Marco Donia posted on LinkedIn: "Melanoma at ESMO24 (Mini Oral Session) My main take-home messages…
Sep 20, 2024, 17:50 | Blog
Daniel Sumarriva: Catching up with good friends, fellow scientists and colleagues at ESMO24
Daniel Sumarriva, Senior Clinical Research Coordinator of the University of Miami Miller School Of Medicine,…
Sep 20, 2024, 17:05 | Blog
Florian Lordick: Lots of important data in gastrointestinal oncology at ESMO24
Florian Lordick, Oncologist, Professor of Medicine at University of Leipzig, shared a post on LinkedIn: "ESMO24…
Sep 20, 2024, 14:47 | Blog
That’s a wrap on ESMO2024 - Agenus
Agenus shared a post on LinkedIn: "That’s a wrap on ESMO2024. Our team had a great…
Sep 20, 2024, 13:55 | Blog
Wungki Park: Successful meeting at ESMO24
Wungki Park, Gastrointestinal Oncologist at the Memorial Sloan Kettering Cancer Center, posted on X: "Barcelona always…
Sep 20, 2024, 12:57 | Blog
Neeraj Agarwal: The 1st results of the ph3 Niagara trial of cisplatin + gemcitabine +/- durvalumab in MIBC
Neeraj Agarwal shared a post on X: "Breaking news (practice changing) from ESMO24, Tom Powles…
Sep 20, 2024, 12:55 | Insight
Tom Powles: The 1st disitimab Vedotin and pembro in HER 1-3 urothelial carcinomas
Tom Powles shared a post on X: "The 1st disitimab Vedotin (HER-2 MMAE ADC) and…
Sep 20, 2024, 12:51 | Blog
Matteo Lambertini's final tweet from ESMO24
Matteo Lambertini shared a post on X: "Final tweet from ESMO24 to acknowledge the super…
Sep 20, 2024, 11:51 | Blog
Zena Haddadin: Had the pleasure of meeting Petros Grivas at ESMO24
Zena Haddadin, MD at Jordan University of Science and Technology, shared a post on X:…
Sep 20, 2024, 06:16 | Blog
"Working together in the era of personalized care for older adults with cancer" - SIOG
SIOG posted on X: "The ESMO/SIOG working group hosted a special session today at ESMO24…
Sep 19, 2024, 18:59 | Insight
Vivek Subbiah about “Tumor-Agnostic Biomarker Driven Drug development" at ASCO and ESMO joint session
Vivek Subbiah shared a post on LinkedIn: "It was such a great honor to talk…
Sep 19, 2024, 18:01 | Blog
Caterina Sposetti: Fasting-mimicking diet+neoadjuvant treatment in Early TNBC
Caterina Sposetti, Medical Oncology Fellow, Dana-Farber’s Breast Oncology Center, shared a post on X: "ESMO24.…
Sep 19, 2024, 16:38 | Blog
Benjamin Besse: Impressive benefit for Lenvatinib-Pembrolizumab in patients with thymic carcinoma and B3 thymoma
Estela Rodriguez shared a post by Benjamin Besse, Head of Clinical Research at Gustave Roussy,…
Sep 19, 2024, 15:36 | Blog
Xiuning Le: Busy two weeks WCLC24 and ESMO24
H. Jack West, Vice President of Clinical Development at Summit Therapeutics in Menlo Park, California, shared…
Sep 19, 2024, 14:45 | Blog
Sarah Scagliarini: ESMO24 take home message
Sarah Scagliarini, Medical Oncologist, Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli, Italy, shared a post…
Sep 19, 2024, 14:44 | Blog
Amalya Sargsyan: Abeid Athman was awarded Best Poster at ESMO24
Amalya Sargsyan posted on X: "Hugee Congraaats to my friend Abeid Athman who was awarded…
Sep 19, 2024, 14:31 | Insight
Ramon Salazar: ESMO24 was one of the best meetings ever
Ramon Salazar shared a post on X: “A great thank you to all organizers and…
Sep 19, 2024, 14:24 | Insight
Elisa Agostinetto: FDA has approved ribociclib with an AI for the adjuvant treatment of HR+/HER2-negative breast cancer
Elisa Agostinetto shared a post on X: “Novartis today announced that the FDA has approved…
Sep 19, 2024, 14:05 | Blog
Yuksel Urun: The conference rooms are no longer enough for GU sessions at ESMO 24
Petros Grivas shared a post by Yuksel Urun on X: "Thrilled to co-chair GU session…
Sep 19, 2024, 11:58 | Insight
Yvonne Diaz: Treatment landscape for EGFR lung cancer
Yvonne Diaz shared on X: “Treatment landscape for EGFR lung cancer is getting more complex…
Sep 19, 2024, 11:55 | Insight
Aakash Desai: Efficacy, Innovation and Cost of FDA-Approved NSCLC Drugs
Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared on LinkedIn: “We're excited to…
Sep 19, 2024, 11:34 | Blog
Dan Goldstaub: Lots of progress at ESMO meeting 2024
Dan Goldstaub, Co-Founder of PhaseV, shared on LinkedIn: "An overwhelming ESMO meeting 2024 ended in…
Sep 19, 2024, 09:23 | Insight
Jessica Lin: Preclinical development and proof-of-concept clinical activity of NVL-655
Jessica Lin shared a post on LinkedIn: "We are pleased to share this article out today…
Sep 19, 2024, 09:19 | Blog
Taha Koray Sahin: Inspiring and valuable mentorship session at ESMO24
Taha Koray Sahin shared a post on X: "Big thanks to Giuseppe Curigliano for the insightful…
Sep 19, 2024, 09:13 | Insight
Vivek Subbiah: Distinct clinical outcomes and biological features of specific KRAS mutants in pancreatic cancer
Vivek Subbiah shared a post on X: "Distinct clinical outcomes and biological features of specific KRAS…
Sep 19, 2024, 09:09 | Blog
Stephanie Graff: Results of DESTINY-Breast12 from ESMO24
Stephanie Graff, Director Breast Oncology at Lifespan Cancer Institute, shared a post on X: "DESTINY…
Sep 19, 2024, 08:59 | Insight
Fantastic talk by Toni Choueiri at ESMO2024 on Ti-Nivo2 trial
Petros Grivas shared a post by Yüksel Ürün on X, adding: "Fantastic talk by brilliant Toni Choueiri…
Sep 19, 2024, 08:36 | Insight
Matteo Lambertini: Andrea Botticelli a massive italian precision medicine effort
Matteo Lambertini shared on X: "Just presented at the ESMO24 Presidential Symposium III by the king…
Sep 19, 2024, 04:53 | Blog
Chandler Park: Talk about a FUN group at ESMO24
Chandler Park shared on X: "Talk about a FUN group at ESMO24." Source: Chandler Park/X…
Sep 19, 2024, 04:32 | Societies
Best of ESMO24
The ESMO Congress 2024 took place in Barcelona, from September 13 to 17, 2024, at…
Sep 18, 2024, 22:59 | Insight
Rami Manochakian: Ponsegromab vs Placebo for treatment of Cachexia in patients with Cancer
Rami Manochakian shared a post on X about a recent paper by John Groarke et…
Sep 18, 2024, 22:54 | Insight
Lizzy Smyth: Radiotherapy does not add to mFOLFIRINOX in borderline resectable Pancreatic Cancer
Lizzy Smyth, Consultant Medical Oncologist in upper GI oncology at Oxford University NHS Foundation Trust,…
Sep 18, 2024, 16:43 | Blog
The first anniversary of ESMO Ambassadors initiative
ESMO posted on X: "ESMO Ambassadors: We are excited to mark the first anniversary of…
Sep 18, 2024, 16:38 | Insight
Pierre Blanchard: The molecular analysis of the PEACE 1 trial
Pierre Blanchard, Radiation Oncology Clinical section chief at Gustave Roussy Cancer Institute, shared on X: "Dr Pobel…
Sep 18, 2024, 15:05 | Blog
Iván R. González: "Presidential Symposium III: Eyes to the Future!" at ESMO 2024
Iván R. González, Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla, shared a post…
Sep 18, 2024, 15:02 | Blog
Jarushka Naidoo: We are ESMO
Jarushka Naidoo shared a post on X: "As ESMO24 draws to a close… thanks to ESMO…
Sep 18, 2024, 15:00 | Blog
Chandler Park: SunRise-1 study ESMO24 update
Chandler Park shared a post on X: "SunRise-1 study ESMO24 update. TAR-200 +/- cetrelimab in patients…
Sep 18, 2024, 14:24 | Blog
Paolo Tarantino: ESMO’s environmental commitment
Paolo Tarantino shared a post on X: "Inspiring to see The European Society for Medical Oncology…
Sep 18, 2024, 13:28 | Blog
Stephen V Liu: An impactful ESMO24
Stephen V Liu shared on X: "An impactful ESMO24 - attending keeps you current with…
Sep 18, 2024, 13:13 | Insight
Jarushka Naidoo: ESMO24 Lung mini-orals
Jarushka Naidoo shared on X: "ESMO24 Lung mini-orals. Randomised phase II trial of inhaled corticosteroids…
All: 259 Posts: 1 - 100
Special Coverage